Medibank shares fall despite big 2030 transformation plans

Let's see what Medibank is planning for a big earnings boost.

Key points
  • Medibank Private plans to accelerate its transformation into a leading health company by expanding its role beyond insurance into the broader healthcare system.
  • The company aims to increase earnings from its health segment to $200 million by FY 2030 and grow its policyholder market share while focusing on wellbeing, primary care, community care, and insurance.
  • CEO David Koczkar emphasises transforming healthcare delivery from treatment to prevention and enhancing digital and personalised care to sustain health outcomes.

Medibank Private Ltd (ASX: MPL) shares are in the spotlight on Wednesday.

In morning trade, the health insurance giant's shares are down almost 1% to $4.86.

meal preparation of healthy food in a family kitchen

Image source: Getty Images

Medibank shares drop despite transformation plans

This morning, the private health insurer unveiled an ambitious plan to accelerate its transformation into a leading Australian health company.

Ahead of a "health immersion" event for investors today, it outlined how it plans to expand its role beyond health insurance and into the broader healthcare system.

Ambitious FY 2030 targets

Medibank has set out a series of long-term aspirations aimed at strengthening its business and driving shareholder value.

The company now aims to lift earnings from its Medibank Health segment to at least $200 million by FY 2030. This is up from $76.7 million in FY 2025.

It also aims to grow its policyholder market share each year in a disciplined way, targeting at least 26.8% by FY 2030.

A third target for 2030 is to double its health and wellbeing engagement, reaching around 10 million Australians by the end of the decade.

Commenting on the targets, Medibank's chief executive officer, David Koczkar, said:

Australia's healthcare system is one of the best in the world, but it is under pressure and urgently needs meaningful transformation to ensure we can keep up with the increasing needs in the community. It's time for the health system to shift from treatment to prevention, from hospital to community, from analogue to digital and from generic to personalised care. Investing in technology and connecting health is critical to accelerate this momentum. These four big shifts are essential to drive the health transition and to sustain the world leading health outcomes we all experience today.

Medibank has been driving the health transition. Over the last decade, we have invested more than $300 million to grow as a health company. We will remain focused on delivering for our customers and long-term value for our shareholders by accelerating our growth strategy, and today we have set out some very clear milestones alongside a new ambition.

Growth in four key segments

To achieve its goals, Medibank plans to focus on four major health areas. They are as follows:

  • Wellbeing – Expanding its Live Better rewards program, workplace health initiatives, and financial wellbeing offerings.
  • Primary care – Growing its general practice network and virtual healthcare services under its Amplar Health brand.
  • Community and acute care – Providing hospital-level care at home and expanding short-stay and rehabilitation services.
  • Health insurance – Continuing to improve value and choice for its 4.2 million policyholders.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »